Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vertex Phase IIb Data On Telaprevir Support 24-Week Dosing For Hepatitis C

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Vertex released positive interim data from Phase IIb studies of its experimental protease inhibitor telaprevir for the treatment of hepatitis C Nov. 2 at the American Association of the Study of Liver Diseases meeting in Boston

You may also be interested in...



Vertex Telaprevir NDA In Treatment-Naive Hep C Now Planned For 2010

Vertex Pharmaceuticals expects to have data available from Phase III trials evaluating the protease inhibitor telaprevir in patients with hepatitis C by mid-2010, the company announced Jan. 23. The program was initiated in March

Vertex Telaprevir Nearing Phase III With Final Installment Of PROVE Program

Vertex expects to complete enrollment in PROVE 3, its Phase IIb trial of the protease inhibitor telaprevir (VX-950), by the end of the second quarter and initiate Phase III trials of the hepatitis C agent in the second half of the year, Executive VP-Medicines Development John Alam told analysts during a Feb. 1 year-end earnings call.

Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s

Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.

Topics

UsernamePublicRestriction

Register

OM011381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel